Schaefer Andreas, Schneeberger Yvonne, Reichart Daniel, Bernhardt Alexander M, Kubik Mathias, Barten Markus J, Wagner Florian M, Kluge Stefan, Reichenspurner Hermann, Philipp Sebastian A
From the *Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany; †Department of Intensive Care Medicine, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and ‡Department of Cardiology and Intensive Care Medicine, Elbe Clinic Stade, Hamburg, Germany.
ASAIO J. 2016 Nov/Dec;62(6):715-718. doi: 10.1097/MAT.0000000000000426.
Over the last decade, the number of heart transplantations declined, and the number of implanted left ventricular assist devices (LVADs) markedly increased. Accordingly, common intensive care interventions rise and present their own challenges, especially because of the necessary anticoagulation regimen. One of these procedures is percutaneous dilatation tracheostomy (PDT). We herein report our experience with 34 patients with LVAD and established phenprocoumon therapy (International normalized ratio 2.1 ± 0.9, partial thromboplastin time 68.9 ± 19.0 seconds) who underwent PDT between 2006 and 2015 at our specialized cardiac surgery intensive care unit. Intraprocedural success was achieved in all cases (34/34 patients) with sufficient placement of the tracheal tube and adequate mechanical ventilation. No retained secretions or tracheostomy tube obstructions were observed during follow-up. In no case, conversion to surgical tracheostomy was necessary. No serious bleeding complications that required urgent or emergent reoperation occurred during or after the PDT procedure. A total of 16 patients (47.1%) died within the first 30 days after LVAD implantation. This is the first report describing outcomes of patients with LVAD under established phenprocoumon therapy and postoperative implemented PDT. PDT is a safe procedure for those patients. It is not connected with bleeding complications and shows a good procedural outcome.
